ITF Press Release
Decision in the case of Andrei Plotniy
London, England, 18 Mar 2010 - The International Tennis Federation announced today that Andrei Plotniy has been found to have committed a Doping Offence under Article C.1 of the Tennis Anti-Doping Programme (presence of a Prohibited Substance in player’s sample).
Mr Plotniy, a 21-year-old tennis player from Russia, provided a sample on 1 November 2009 at the 2009 Challenger in Astana, Kazakhstan. That sample was sent to the WADA-accredited laboratory in Montreal, Canada for analysis, and was found to contain carphedon, a stimulant. Carphedon is a Prohibited Substance under the 2009 WADA List of Prohibited Substances and Prohibited Methods, and is therefore also prohibited under the Tennis Anti-Doping Programme. Mr Plotniy was therefore charged with an anti-doping rule violation under Article C.1 of the Programme and provisionally suspended from competition as from 19 December 2009.
Mr Plotniy asserted that the carphedon had got into his system through his ingestion of Phenotropil, a prescribed medication. He presented evidence that he been prescribed Phenotropil to treat a medical condition, and had consulted the drug information sheet for the product, which did not disclose that it contained a Prohibited Substance. He therefore denied taking any Prohibited Substance knowingly, and denied any intent to cheat.
The ITF accepted Mr Plotniy’s account of the circumstances surrounding his ingestion of Phenotropil, and accepted that he did not intend to enhance his performance. Under the Tennis Anti-Doping Programme, however, it is a player’s strict personal duty to ensure that no Prohibited Substance enters his or her body, whether as an ingredient in a prescription medication or otherwise, unless he/she holds an applicable therapeutic use exemption for such substance. Simply checking the ingredient sheet is not enough. There were many other steps that Mr Plotniy could and should have taken to avoid committing an anti-doping rule violation.
The ITF therefore confirmed Mr Plotniy’s commission of a Doping Offence under Article C.1 of the Tennis Anti-Doping Programme, and determined that Mr Plotniy should be suspended from participation for a period of fifteen months, commencing as from 1 November 2009 and ending on 1 February 2011. The ITF also determined that Mr Plotniy’s results from the 2009 Challenger events in Astana and Khanty-Mansyisk should be disqualified, with resulting forfeiture of the ranking points and prize money that he won at those events.
The Tennis Anti-Doping Programme is a comprehensive and internationally recognised drug-testing programme that applies to all players competing at tournaments sanctioned by the ITF, ATP World Tour, and Sony Ericsson WTA Tour. Players are tested for substances prohibited by the World Anti-Doping Agency and upon a finding that a Doping Offence has been committed, sanctions are imposed in accordance with the requirements of the World Anti-Doping Code. More background information on the Programme, sanctions, tennis statistics and related information can be found at www.itftennis.com/antidoping